Free Trial

PMV Pharmaceuticals Q1 2023 Earnings Report

PMV Pharmaceuticals logo
$1.11 -0.04 (-3.48%)
As of 03/28/2025 04:00 PM Eastern

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

PMV Pharmaceuticals Earnings Headlines

PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
PMV Pharmaceuticals sees cash runway to end of 2026
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile

More Earnings Resources from MarketBeat